11 Sep 2017 | Business Wire
Sales of $4.8 million in the quarter were 80 per cent higher than in the comparable period of the prior year and were 29 per cent higher than the second quarter of 2017.
11 Aug 2017 | The Weed Blog
Few drugs scheduled as a Schedule I drug – that is, a drug without medical benefit and with a high potential for abuse and addiction – have been as controversial lately as marijuana.
11 Aug 2017 | Marijuana
Far from a gateway drug, marijuana helps today’s senior citizens exit the vicious cycle of pharmaceuticals and addiction. Although marijuana was once considered a dangerous recreational drug by many senior citizens, today’s elderly are among the fastest growing demographic within the industry.
11 Aug 2017 | Insurance Business
Companies need to start thinking about the therapeutic benefits
9 Aug 2017 | Perth Now
AUSTRALIAN drug regulators have granted what is believed to be the first licence to manufacture and supply medical cannabis in WA.
9 Aug 2017 | Benzinga
GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH) shares initially jumped Monday after disappointing data from a leading drug candidate sent shares of Zynerba Pharmaceuticals Inc
8 Aug 2017 | Proactiveinvestors UK
Queensland Bauxite (ASX:QBL) - Potential market updates are expected regarding production, marketing and distribution agreements
8 Aug 2017 | Lancashire Telegraph
A shop thought to be the first in the UK dedicated to a cannabis compound with claimed health benefits is due to open in East Lancashire.
8 Aug 2017 | Finfeed.com
The Swiss launch of CPH’s proprietary formulated hemp-based complementary feed products for companion animals, anibidiol® 1.25 and anibidiol® 2.5, is planned for the fourth quarter of this year.
8 Aug 2017 | Streetwise Reports
A preclinical research and development company that is developing a proprietary cannabinoid-based combination drug therapy for the treatment of concussions and traumatic brain injury, has just completed a reverse takeover.